Dublin, April 19, 2024 (GLOBE NEWSWIRE) -- The "Premature Labor (PL) -Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.
This reports provides a data-driven overview of the current and future competitive landscape in PL therapeutics.
In 2023, more than 5,000,000 prevalent cases of pulmonary lymphangioleiomyomatosis (PL) are expected across 16 countries covered in an epidemiology forecast. The majority of drugs used to treat PL are generic, with beta-2 adrenergic receptor antagonists being the predominant treatment option.
Despite this, only one out of the 13 drugs in the pipeline for PL has reached the Phase III stage of development, indicating a need for further research and development in this area. Over the past decade, more than 25% of clinical trials for PL have been conducted in North America, highlighting the region's significant contribution to PL research.
Additionally, in the past 10 years, acquisition has been the most common type of deal involving companies developing PL assets in both North America and Europe, reflecting ongoing investment and interest in PL therapeutics.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the PL market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PL market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Key Topics Covered:
1 Preface
1.1 Contents
1.2 Report Scope
1.3 List of Tables and Figures
1.4 Abbreviations
2 Key Findings
3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview
4 Marketed Drugs Assessment
4.1 Leading Marketed Drugs
4.2 Overview by Mechanism of Action
4.3 Overview by Route of Administration
4.4 Marketed Drugs Profiles and Sales Forecasts
5 Pricing and Reimbursement Assessment
5.1 Annual Therapy Cost
5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
6.1 Phase III Pipeline Drugs
6.2 Overview by Development Stage
6.3 Overview by Molecule Type
6.4 Overview by Mechanism of Action
6.5 Overview by Route of Administration
6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
6.7 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
7.1 Historical Overview
7.2 Overview by Phase
7.3 Overview by Status
7.4 Overview by Phase for Ongoing and Planned Trials
7.5 Trials with Virtual Components
7.6 Geographic Overview
7.7 Single-Country and Multinational Trials by Region
7.8 Top 20 Sponsors with Breakdown by Phase
7.9 Top 20 Sponsors with Breakdown by Status
7.10 Overview by Endpoint Status
7.11 Overview by Race and Ethnicity
7.12 Enrollment Data
7.13 Top 20 countries for Trial Sites
7.14 Top 20 Sites Globally
7.15 Feasibility Analysis - Geographic Overview
7.16 Feasibility Analysis - Benchmark Models
8 Deals Landscape
8.1 Mergers, Acquisitions, and Strategic Alliances by Region
8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
9.1 Key Market Players
10 Future Market Catalysts
11 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/e9grl8
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
